GLP-1: Glucagon-like peptide-1; RA: receptor agonist. ACS ... in ongoing clinical trials including albiglutide, semaglutide, dulaglutide and ITCA650. Published and preliminary data have shown ...

GLP-1 receptor agonists emerge as promising therapies ... Several GLP-1RAs, including liraglutide, semaglutide, and tirzepatide, have been evaluated in clinical trials for their efficacy in ...

Seven different GLP-1 receptor agonists were investigated among the trials, including semaglutide (also known as Ozempic or Wegovy), dulaglutide (Trulicity) and liraglutide (Victoza). The results ...

Not long after the FDA wrapped its preliminary investigation of GLP-1 receptor agonists and suicidal thoughts or actions, the ...

GLP-1 receptor agonists (GLP-1RAs), including liraglutide, semaglutide, and tirzepatide, were originally developed for managing type-2 diabetes. However, due to their success in helping with ...

Opens in a new tab or window In January, we reported on the FDA clearing GLP-1 receptor agonists of suicidality ... based on two studies of patients on semaglutide (Ozempic, Rybelsus, Wegovy ...

Anti-obesity medication use was associated with reduced alcohol consumption among patients in a telehealth medical weight ...

Undiagnosed or untreated EPI could result in muscle loss since the patient isn’t absorbing the necessary nutrients.

Individual usage of glucagon like peptide 1 receptor agonists reduced the risk of hospitalization due to alcohol and substance use disorders.